Clinical-note study finds rising BPC-157 use, with benefits still unestablished

A September analysis of U.S. clinical records has documented increasing use of BPC-157, an unapproved peptide promoted for healing and recovery. The finding matters because exposure to products obtained outside conventional prescribing can remain difficult to detect, even when users subsequently seek medical care.

The study was posted September 7 on Preprints.org and received wider attention through Reuters reporting September 15, updated September 16. It has not undergone peer review. Its contribution is evidence about documented use and the limitations of monitoring it; it does not establish a treatment benefit.

What the records reveal

Researchers at nference examined de-identified clinical notes using a large language model, with physician checks of sampled extractions. Their retrospective observational study identified 1,039 patients with documented BPC-157 use. Newly documented quarterly users increased from four in the first quarter of 2020 to 134 in the first quarter of 2026.

These are documentation counts, not a national estimate of consumption. A patient's first recorded mention may follow actual initiation, and a rise in recorded use can reflect changes in disclosure or recognition as well as exposure.

Reuters reported that the underlying network included more than 15 million patients' records. Conventional tracking is difficult because BPC-157 lacks a National Drug Code, making written clinical notes an important source of information. Recorded reasons for use ranged from pain and sports injuries to gastrointestinal complaints.

Why reported improvement cannot establish efficacy

The study lacked a placebo or untreated comparison group. Reuters also highlighted the absence of standardized treatment and outcome assessment, and the frequent use of other drugs, rehabilitation or surgery alongside BPC-157. Those features prevent attribution of improvement to the peptide.

In the preprint, response direction was missing for 685 patients, or 65.9% of documented users. Among the 354 with a recorded direction, 79% had improvement documented. That selected subgroup cannot supply a reliable treatment success rate.

For interpretation, the missing denominator is crucial: patients without an outcome entry cannot be counted as improved, unchanged or unharmed. Routine notes answer different questions from a trial that prospectively measures the same outcome in every participant. Sparse documentation of adverse events likewise cannot establish that harms are uncommon.

Regulatory concerns remain relevant

FDA's current safety-information page identifies concerns about BPC-157 involving immune reactions, peptide-related impurities and characterization of the active ingredient. The agency says available safety information is insufficient to determine whether administration would harm people. These are uncertainties requiring investigation, rather than a quantified estimate of risk for every product or user.

The FDA's July 23–24 advisory-committee agenda considered BPC-157-related substances for the 503A bulks list, with ulcerative colitis identified as the evaluated use. That narrow regulatory question should not be read as validation of the broader injury-recovery and performance claims surrounding the compound.

The practical implication is a need for better exposure records and prospective research. For a future study to answer the clinical question, investigators would need a characterized product, an appropriate comparison, consistent outcome measurements and active safety follow-up. Until those elements are available, the new analysis helps explain what is appearing in medical records without resolving whether BPC-157 improves recovery or preserves health.